BTI BiOasis Technologies Inc

biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that it has entered
into a research collaboration agreement with Brussels, Belgium-based UCB
(Euronext Brussels: UCB), to evaluate biOasis's Transcend technology in the area
of the delivery of therapeutic compounds to the brain. In connection with this
agreement, biOasis will conduct certain experiments to provide UCB with
confirmation of the Transcend technology as it relates to the delivery of
therapeutic compounds owned by UCB to the CNS.


"UCB is a highly respected biopharmaceutical company with a broad global
presence and a deep pipeline. We're very pleased to be commencing this
collaboration with UCB whom we believe have some tremendous targets for our
Transcend vector," said Rob Hutchison, CEO. "The interest from within the
industry on our Transcend technology is clearly widening and this agreement with
UCB is a prime example of that. The work will start over the next few months and
carry into the New Year. We are looking forward to working with the UCB
scientists to successfully achieve the objectives we have set out in agreement."


Financial Terms were not disclosed.

ABOUT UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company
focused on the discovery and development of innovative medicines and solutions
to transform the lives of people living with severe diseases of the immune
system or of the central nervous system. With more than 8,000 people in about 40
countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is
listed on Euronext Brussels (symbol: UCB).


ABOUT BIOASIS & TRANSCEND

biOasis Technologies Inc. is a biopharmaceutical company engaged in the
development and commercialization of products for the diagnosis and treatment of
neurological diseases and disorders. Its products and technologies are intended
for use within the healthcare and life science research markets. biOasis is
developing a proprietary carrier for the transport of therapeutic and imaging
agents across the blood-brain barrier - Transcend. Current initiatives within
the Transcend program include production of materials for preclinical studies
and conjugation to a range of small molecule and biologic therapeutics. To
address the unmet clinical need to transport drugs across the blood brain
barrier, biOasis intends to license Transcend to multiple corporate partners.


Forward Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that


may not be based on historical fact, including without limitation statements
containing the words "believe", "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", "expect" and similar expressions. Such forward-looking
statements or information involve known and unknown risks, uncertainties and
other factors that may cause our actual results, events or developments, or
industry results, to be materially different from any future results, events or
developments express or implied by such forward-looking statements or
information. Such factors include, among others, our stage of development, lack
of any product revenues, additional capital requirements, risk associated with
the completion of clinical trials and obtaining regulatory approval to market
our products, the ability to protect our intellectual property, dependence on
collaborative partners and the prospects for negotiating additional corporate
collaborations or licensing arrangements and their timing. Specifically, certain
risks and uncertainties that could cause such actual events or results expressed
or implied by such forward-looking statements and information to differ
materially from any future events or results expressed or implied by such
statements and information include, but are not limited to, the risks and
uncertainties that: we may not be able to successfully develop and obtain
regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's, or
future products in our targeted corporate objectives; our future operating
results are uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent events or
circumstances, except as required by law.


On Behalf of the Board of Directors 

Rob Hutchison Chairman & CEO

FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
(778).383.3280
rob@bioasis.ca

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Giu 2023 a Giu 2024